title: Effect of sulforaphane on growth inhibition in human brain malignant glioma GBM 8401 cells by means of mitochondrial- and MEK/ERK-mediated apoptosis pathway.
abstract: In recent studies, sulforaphane (SFN) has been seen to demonstrate antioxidant and anti-tumor activities as well as potent chemopreventive action against cancer. The present study investigates the anti-proliferation (using MTT assay, SFN demonstrated cytotoxic activity against GBM 8401 cell with IC(50) values at 35.52 μM) and induced apoptosis of SFN 24-h treatment in the cells of human brain malignant glioma GBM 8401 cells. We studied the MMP, caspase, MEK/ERK activation, and NF-κB transcription factor activity. Our results indicate that SFN inhibits cell proliferation as well as the activation of apoptosis in GBM 8401 cells. Both effects increased in proportion to the dosage of SFN, and apoptosis was induced via mitochondria- and caspase-dependent pathways. Daily s.c. injections of SFN for 3 weeks in severe combined immunodeficient mice (SCID) with GBM8401 s.c. tumors resulted in a decrease in mean tumor weight of 69-75 % compared with vehicle-treated controls. Our findings suggest that, in addition to the known effects on cancer prevention, SFN may provide antitumor activity in established malignant glioma.
authors.affiliation: Department of Neurosurgery, Tainan Sin-Lau Hospital, Tainan, Taiwan. slh3353@sinlau.org.tw
authors.forename: Tzuu-Yuan
authors.initials: TY
authors.lastname: Huang
authors.forename: Weng-Cheng
authors.initials: WC
authors.lastname: Chang
authors.forename: Miin-Yau
authors.initials: MY
authors.lastname: Wang
authors.forename: Yun-Ru
authors.initials: YR
authors.lastname: Yang
authors.forename: Yi-Chiang
authors.initials: YC
authors.lastname: Hsu
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity*; D017209:Apoptosis / Q000187:drug effects*; D020169:Caspases / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism*; D059585:G1 Phase Cell Cycle Checkpoints / Q000187:drug effects; D005910:Glioma / Q000188:drug therapy; D006801:Humans; D017879:Isothiocyanates; D020935:MAP Kinase Signaling System; D051379:Mice; D016513:Mice, SCID; D016328:NF-kappa B / Q000378:metabolism; D013454:Sulfoxides; D013861:Thiocyanates / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity*; D014183:Transplantation, Heterologous
chemical_list: D016588:Anticarcinogenic Agents; D017879:Isothiocyanates; D016328:NF-kappa B; D013454:Sulfoxides; D013861:Thiocyanates; D048049:Extracellular Signal-Regulated MAP Kinases; D020169:Caspases; C016766:sulforaphane